Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1

Interventions

Everolimus 15Magnetic Resonance Spectroscopy 8lutetium Lu 177 dotatate 7pasireotide 5gallium Ga 68 dotatate 5Cisplatin 5Specimen Handling 4Positron Emission Tomography Computed Tomography 4Nivolumab 4Fluorodeoxyglucose F18 4Carboplatin 4Temozolomide 3Paclitaxel 3Octreotide 3Lutetium-177 3Ga(III)-DOTATOC 3Etoposide 3(177)Lu-DOTA-EB-TATE 3vandetanib 2pembrolizumab 2olaparib 2fluorodopa F 18 2dabrafenib 2copper dotatate CU-64 2cemiplimab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Trastuzumab 2Radiotherapy 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Radiofrequency Ablation × Endocrine × Clear all
NCT00103155 2013-09-20

Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡